AMLX Amylyx Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1658551 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.3%
TTM net income YoY42.5%
TTM EPS YoY53.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin23,660.3%
Net margin22,448.4%
FCF margin23,236.1%
EBITDA margin23,573.5%
Returns
ROE-56.5%
ROA-48.7%
ROIC (approx.)-107.5%
Asset turnover-0.00x
Leverage & solvency
Liabilities / assets8.5%
Debt / equity0.00x
Current ratio13.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue-10.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $0 | -$665,000 |
| Cost of revenue | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | $0 | $0 | $0 | $0 | -$665,000 |
| R&D expense | $28.35M | $23.77M | $27.61M | $21.21M | $19.86M | $27.22M | $22.12M | $22.89M |
| SG&A expense | $21.31M | $21.93M | $16.17M | $15.39M | $16.17M | $15.64M | $15.68M | $17.10M |
| Operating income | -$49.66M | -$45.69M | -$43.78M | -$36.60M | -$36.03M | -$42.86M | -$37.80M | -$40.65M |
| Pretax income | — | — | — | -$32.95M | -$34.39M | -$41.44M | -$35.91M | -$38.18M |
| Income tax | — | — | — | $46,000 | $0 | $0 | $0 | -$635,000 |
| Net income | -$45.49M | -$43.42M | -$41.28M | -$33.00M | -$34.39M | -$41.44M | -$35.91M | -$37.55M |
| EBITDA | -$49.62M | -$45.65M | -$43.68M | -$36.50M | -$35.91M | -$42.72M | -$37.65M | -$40.49M |
| EPS (basic) | -0.38 | -0.39 | -0.37 | — | -0.37 | -0.46 | -0.42 | — |
| EPS (diluted) | -0.38 | -0.39 | -0.37 | — | -0.37 | -0.46 | -0.42 | — |
| Weighted avg. shares (diluted) | 118.94M | 111.20M | 110.56M | — | 93.33M | 89.14M | 85.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $240.09M | $49.33M | $229.14M | $226.65M | $225.18M | $58.09M | $59.76M | $77.39M |
| Short-term investments | $528.04M | $201.43M | $50.63M | $90.33M | $118.81M | $122.74M | $144.30M | $99.11M |
| Receivables | — | — | — | $88,000 | $132,000 | $103,000 | $300,000 | $447,000 |
| Current assets | $778.86M | $256.34M | $285.02M | $323.67M | $353.38M | $186.89M | $216.14M | $189.43M |
| PP&E, net | $191,000 | $199,000 | $212,000 | $310,000 | $399,000 | $445,000 | $816,000 | $961,000 |
| Total assets | $786.79M | $264.56M | $293.60M | $332.64M | $362.74M | $194.60M | $219.68M | $193.63M |
| Current liabilities | $29.05M | $21.15M | $15.97M | $22.69M | $25.79M | $21.42M | $17.93M | $28.41M |
| Total liabilities | $33.06M | $25.40M | $20.44M | $27.39M | $30.75M | $26.72M | $18.26M | $28.87M |
| Shareholders' equity | $753.74M | $239.17M | $273.16M | $305.26M | $332.00M | $167.88M | $201.42M | $164.76M |
| Shares outstanding | 128.54M | 111.37M | 111.03M | 109.88M | 109.77M | 89.16M | 89.08M | 68.63M |
| Cash flow statement | ||||||||
| Operating cash flow | -$33.67M | -$31.42M | -$36.88M | -$27.90M | -$30.37M | -$25.25M | -$39.82M | -$59.01M |
| Capital expenditure | $25,000 | — | — | $86,000 | $24,000 | $17,000 | $11,000 | $20,000 |
| Free cash flow | -$33.70M | — | — | -$27.99M | -$30.39M | -$25.27M | -$39.84M | -$59.03M |
| Investing cash flow | -$325.67M | -$149.80M | $36.26M | $29.47M | $5.24M | $22.99M | -$43.66M | $64.98M |
| Financing cash flow | $550.16M | $1.48M | $3.22M | -$208,000 | $191.61M | -$31,000 | $65.66M | $110,000 |
| Depreciation & amortization | $33,000 | $43,000 | $98,000 | $108,000 | $120,000 | $141,000 | $156,000 | $160,000 |
| Stock-based compensation | $10.37M | $8.32M | $6.12M | $6.39M | $7.08M | $7.35M | $6.83M | $6.74M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.